Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Recruiting · NCT07468136 · Registry updated 2026-06-24Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, anaplastic oligodendroglioma, astrocytoma (excluding glioblastoma), astrocytoma, IDH-mutant, grade 3, astrocytoma, IDH-mutant, grade 4, diffuse astrocytoma, epithelial neoplasm, follicular lymphoma, glioblastoma, glioma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, malignant glioma, neoplasm, neuroepithelial neoplasm, oligodendroglioma, primitive neuroectodermal tumor | Recruiting | Phase 1 / Phase 2 | 2026-06-24 | NCT07468136 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Mayo Clinic | 970 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | United States | 687 |